DelveInsight’s ‘Uveitis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Uveitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan
Study Period: 2016-2027
Uveitis - Disease Understanding and Treatment Algorithm The DelveInsight Uveitis market report gives the thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.
Uveitis Epidemiology The Uveitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken. The disease epidemiology covers the prevalence of both Infectious and Non-Infectious Uveitis (NIU). Prevalence of NIU is further segmented into four types basis of sub-type [Intermediate Uveitis, Pan-Uveitis, Posterior Uveitis, Anterior noninfectious uveitis (aNIU] in 7MM. According to DelveInsight, the prevalent cases of Uveitis was 706,666 in 2016 in 7 MM, of which 643,721 cases were of Non-Infectious Uveitis (NIU). As per DelveInsight estimation prevalent cases of Uveitis is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States account for highest prevalent cases of Uveitis with 392,035 prevalent cases in 2016 followed by France.
Uveitis Drug Chapters This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The market of Uveitis is dominated with corticosteroids, immunosuppressants and biologics. Off-label corticosteroids, immunosuppressive and biologics are also being used for Uveitis. Corticosteroids are used as first line of therapy for treatment of Uveitis. Currently four corticosteroids namely Durezol, Retisert, Ozurdex and Triesence are being used. The first approved monoclonal antibody approved for the treatment of Uveitis was Humira (Adalimumab). This report includes detailed chapters of marketed along with the promising upcoming therapies.
Uveitis Market Outlook The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Uveitis market is expected to grow during the forecasted period of 2018-2027 at a CAGR of XX% owing to the launch of nine drugs (presently in Phase III). Uveitis Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.
Uveitis Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Uveitis Report Insights • Patient Population • Therapeutic Approaches • Pipeline Analysis • Market Size and Trends • Market Opportunities • Impact of upcoming Therapies
Key Benefits • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Uveitis market • Organize sales and marketing efforts by identifying the best opportunities for Uveitis market • To understand the future market competition in the Uveitis market.
Our reports have been used by over 10K customers, including:
Cancer involves abnormal and uncontrolled cell growth which may spread to other parts of the body as well. According to GLOBOCAN, in 2015, approximately 15.2 Million incidences of cancer were registered all across the globe. Out of total, US accounted for approximately 1.7 Million incidences of this deadly disease....
The report presents a detailed analysis of the Aeromonads diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Aeromonads definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:
This new report provides comprehensive analysis of the ten POC market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Rationale The growing economic pressures...
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity and the structural difference in the mind. Symptoms of the Attention Deficit Hyperactivity...
The global viral vector manufacturing market is projected to grow at a CAGR of 20.0%. The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%. The growth of this market is expected to be driven by rising prevalence of target diseases and disorders,...
The autoinjectors market is projected to grow at a CAGR of 24.2% during the forecast period. The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period. Growing prevalence of targeted therapies, rising incidence...